Advertisement

Topics

3rd Millennium, Inc Company Profile

14:04 EST 15th December 2018 | BioPortfolio

3rd Millennium, Inc. is the leading provider of custom informatics systems, management consulting services, and packaged software products for the life sciences.
Since 1994, we have helped both public and private life science institutions manage, plan, specify, design, build, and integrate informatics systems to support their research and development programs.

We provide our clients with outstanding value by combining our deep knowledge of life science R&D, cutting edge informatics technologies, a highly efficient methodology, and an extensive portfolio of designs, code libraries, frameworks, and implemented systems.

Our staff consists of Ph.D. level scientists and senior software engineers that work closely with our clients in tightly integrated teams. We have an unmatched record of completing projects on-time and on-budget while exceeding user expectations.

Location

391 Totten Pond Road, Suite 104
Waltham
Massachusetts
2451
United States of America

Contact

Phone: 781-890-4440
Email: eSales@3rdmill.com


News Articles [27 Associated News Articles listed on BioPortfolio]

QIAGEN: Short-Engagement von Millennium International Management gesteigert

KJ Venlo (www.aktiencheck.de) - Leerverkäufer Millennium International Management LP erhöht Netto-Leerverkaufsposition in Aktien der QIAGEN N.V. geringfügig: Die Hedgefonds-Manager von Millennium I...

Millennium:Looking for First in Class and Best in Class Opportunities in Oncology and Hematology

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to Dan Curran, Vice President, Corporate Development at Millennium

QIAGEN: Short-Engagement von Millennium International Management weiter gesteigert

KJ Venlo (www.aktiencheck.de) - Leerverkäufer Millennium International Management LP hebt Netto-Leerverkaufsposition in Aktien der QIAGEN N.V. wieder an: Die Leerverkäufer-Attacke des Hedgefonds Mi....

QIAGEN: Leerverkäufer Millennium International Management bleibt im Rückwärtsgang

KJ Venlo (www.aktiencheck.de) - Leerverkäufer Millennium International Management LP verringert Netto-Leerverkaufsposition in Aktien der QIAGEN N.V. wieder sichtbar: Die Leerverkäufer des Hedgefond....

QIAGEN: Leerverkäufer Millennium International Management hält QIAGEN unter Beschuss

KJ Venlo (www.aktiencheck.de) - Leerverkäufer Millennium International Management LP erhöht Netto-Leerverkaufsposition in Aktien der QIAGEN N.V. deutlich: Die Leerverkäufer des Hedgefonds Millenniu...

The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic across Europe

A new report, by Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF), published... The post The Burden of Atrial Fibrillati...

Sareum and Structure: An Interview with Tim Mitchell, CEO

Fintan Walton talks to Tim Mitchell, CEO, Sareum, about founding the company with David Williams and John Reader, as a spin-out from Millennium Pharmaceuticals' Structure-based Discovery Department. T...

Americans farmed a huge and raucous parrot a millennium ago

Drugs and Medications [0 Results]

None

PubMed Articles [34 Associated PubMed Articles listed on BioPortfolio]

Assessing the performance of the least developed countries in terms of the Millennium Development Goals.

This article presents a proposal for assessing the progress of least developed countries towards the achievement of the Millennium Development Goals over the period 2000-2015. Composite indices are bu...

Mental Health of Children of Deployed and Nondeployed US Military Service Members: The Millennium Cohort Family Study.

Families experience multiple stressors as a result of military service. The purpose of this study was to investigate the associations among service member deployment experiences, family and military f...

Addressing climate change through a nursing lens within the framework of the United Nations Sustainable Development Goals: A scoping review.

In 2000, the United Nations (UN) introduced the Millennium Development Goals (MDG), described as a global movement with the primary aim of ending world-wide poverty ("Millennium Summit," 2000). The se...

Neonatal mortality in the framework of the Millennium Development Goals and new post-2015 goals.

Correction: Pioneer farming in southeast Europe during the early sixth millennium BC: Climate-related adaptations in the exploitation of plants and animals.

[This corrects the article DOI: 10.1371/journal.pone.0197225.].

Clinical Trials [14 Associated Clinical Trials listed on BioPortfolio]

The Millennium Villages Project: Assessing the Impact on Child Survival and the Millennium Development Goals in Sub-Saharan Africa

The Millennium Villages Project involves the coordinated and simultaneous delivery of a package of proven interventions in health, agriculture, infrastructure and education. The project wo...

Treating Sleep Problems in VA Adult Day Health Care

The Veterans Millennium Health Care and Benefits Act (Millennium Act) of 1999 mandated the Department of Veterans Affairs (VA) to provide non-institutional long-term care to veterans. Adul...

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and...

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease...

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM) for patients who have received at least one pri...

Companies [59 Associated Companies listed on BioPortfolio]

Millennium Dental Technologies, Inc.

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust cl...

Millennium Pharmaceuticals, Inc.

Millennium Pharmaceuticals, The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical developme...

Millennium: The Takeda Oncology Company

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical de...

Millennium Pharmacy Systems, Inc.

Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for th...

Millennium Marketing®

The mission of Millennium Marketing® is to provide businesses with information that will help them make more effective decisions.At Millennium Marketing® we will always do what's in the best int...

More Information about "3rd Millennium, Inc" on BioPortfolio

We have published hundreds of 3rd Millennium, Inc news stories on BioPortfolio along with dozens of 3rd Millennium, Inc Clinical Trials and PubMed Articles about 3rd Millennium, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 3rd Millennium, Inc Companies in our database. You can also find out about relevant 3rd Millennium, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record